Nekacin (Amikacin Sulfate)

Amikacin exerts its antibacterial effect by binding to the 30S subunit of bacterial ribosomes. This binding disrupts the initiation of protein synthesis and causes misreading of messenger RNA, leading to the production of faulty proteins and ultimately bacterial cell death. Its action is concentration‑dependent and primarily bactericidal.

The dosing regimen for Nekacin is individualized by the prescribing clinician based on the type and severity of infection, the patient’s renal function, body weight, and other clinical factors. The prescriber determines the appropriate dose, frequency, and duration, and adjustments are made as needed during therapy.

Limited clinical data exist regarding the use of amikacin during pregnancy and lactation. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case carefully and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Nekacin product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed), and assist with import documentation.

Compared with older aminoglycosides such as gentamicin, amikacin (Nekacin) often retains activity against many bacterial strains that have developed resistance to gentamicin. It provides a broader spectrum against resistant Gram‑negative organisms and may require less frequent dosing. However, both drug classes share similar safety concerns, including nephrotoxicity and ototoxicity, so monitoring remains essential.

Nekacin should be stored in a refrigerator at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain conditions throughout to preserve stability and potency.

Nekacin is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) administration. The medication is reconstituted with the appropriate diluent according to the product label, then infused over the recommended period or injected intramuscularly. Administration technique and infusion rate are determined by the prescriber based on the clinical situation.

The most critical adverse effects to monitor are nephrotoxicity, which can lead to acute kidney injury, and ototoxicity, which may cause irreversible hearing loss or balance disturbances. Additionally, severe hypersensitivity reactions such as anaphylaxis and potentiation of neuromuscular blockade are rare but serious concerns that require immediate medical attention.

Nekacin is contraindicated in patients with a known hypersensitivity to amikacin or any other aminoglycoside. It should also be avoided in individuals with pre‑existing severe renal impairment or significant hearing loss unless the benefits clearly outweigh the risks and close monitoring is possible.